Bristol Myers Squibb™ Foundation

National Medical Fellowships

The Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program (DCTCDP) Overview

Winter 2020/2021

Welcome

- Welcome and Introductions
  - Catharine Grimes, Director, Bristol Myers Squibb Foundation (BMSF)
  - Joy L. Jones, Chief Program Officer, National Medical Fellowships (NMF)

- BMSF DCTCDP National Advisory Committee (NAC)
  - Robert A. Winn, MD, NAC Chair

- Program Overview
  - Catharine Grimes, MBA
  - Joy L. Jones, PhD

Bristol Myers Squibb™ Foundation

The Bristol Myers Squibb Foundation empowers partners to build innovative solutions to advance health equity and improve access to quality healthcare for patients by focusing grant making on communities most at risk of suffering the impacts of serious diseases in the regions of the world that are hardest hit.

National Medical Fellowships

building the next generation of healthcare leaders

NMF's vision is to empower and support aspiring physicians and health professionals underrepresented in medicine to contribute to the health of our nation.

We envision a diverse healthcare workforce which will have the leadership, commitment and cultural competency to achieve health equity.

NMF's mission is to provide scholarships and support for underrepresented minority students in medicine and the health professions.

Bristol Myers Squibb™ Foundation

National Medical Fellowships

Diversity in Clinical Trials Career Development Program (DCTCDP)

National Advisory Committee Chair (NAC)

Dr. Robert Winn

Director, Massey Cancer Center
Professor, Division of Pulmonary Disease and Critical Care Medicine
Virginia Commonwealth University

Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program

Catharine Grimes, MBA
Director, Bristol Myers Squibb Foundation

Joy L. Jones, PhD
Chief Program Officer, National Medical Fellowships

Bristol Myers Squibb™ Foundation | National Medical Fellowships

The need for diversity in clinical trials

Definition of Diversity in Clinical Trials

- Engage a patient population that mirrors the epidemiology of the disease studied
- Assure the ecosystem around the trials reflects diverse populations being served. Includes research sites, principal investigators, and extended care teams
- Design in inclusivity from start

Benefits of Diversity in Clinical Trials

- Better Science. Safety and efficacy of new medicines should be assessed in the patients with the condition
- Personalized Medicine. Understanding the range of different responses to treatments based on genetic variations
- Data. Better inform treatment decisions by making new options available to patients
- Address disparity and inequity

Current State of Clinical Trials

- Black Americans represent 13% of the US population but reflect only about 4% of participants in clinical trials
- Hispanics represent 16% of the US population but only about 3% of clinical trial participants
- In general 80% of patients taking part in clinical trials are white*

Diversity in Clinical Trials Career Development Program

Bristol Myers Squibb Foundation $100 MM Commitment over 5 years

*Comprehensive and integrated approach to increase diversity in clinical trials through workforce **development AND clinical trial site development** in underserved communities where underrepresented patients receive care.*

Do better in urban areas:	Support established clinical trials sites/centers of excellence to engage with nearby community and safety net healthcare delivery institutions to enhance their clinical trial capacity and to collaborate on research.
Build capacity in areas with high disease burden:	Train a network of people who can help stand up a clinical trial in underserved areas that connect with community due to community outreach and engagement training, and with funding from an infrastructure fund.

Diversity in Clinical Trials Career Development Program

Goals

- To transform the clinical research landscape by building and strengthening partnerships between clinical investigators and the communities where their patients reside.
- To facilitate an approach to clinical and translational research that is community-informed, designed and conducted.

Approach

- Provide training and resources to build a network of URM clinical investigators with community engagement and research skills.
- Expand the number of community-based sites with the capacity to conduct clinical and translational research.

Outcome

Increased participation of diverse patients in clinical and translational research.

Impact

Improved public health through an increase in the development of new drugs, vaccines and therapeutic products that are effective in all populations.

Key Program Elements

Commitment	• Train and develop 250 new clinical investigators dedicated to increasing diversity in clinical trials (~50/year) • Provide immersive community-based experiences in clinical trial research to 250 underrepresented minority medical students (Note: The Pipeline program will launch in the summer of 2022. Applications will open in Oct/Nov 2021).
Award	$120K/year for 2 years; require at least 40% of Scholar's time (Note: Awards will be given to organizations, not to individuals.) **Guidance for the award:** It is expected that the award will cover a percentage of the Scholar's salary to garner 40% of his/her time. Additionally, funds can be used toward a portion of a research assistant/coordinator salary. If funds are used for indirect costs, the amount cannot exceed $10,000 or 10% of the recommended salary offset.
Mentoring	Scholar will be mentored by a Principal Investigator at an established clinical trial site, and will substantively participate in the PI's **active** clinical trial (it is not expected that the scholar will have his/her own clinical trial). **Note: The clinical trial must be a drug interventional study.***
Training	Scholars will be trained in investigator-initiated and industry-sponsored clinical trials, as well as in community outreach and engagement processes and methods.
Pipeline program	Scholar will serve as a mentor to an URM medical student during the 2nd program year. 250 URM medical students (50/year) will participate in a 6- to 8-week summer immersion program learning the basics of clinical trials and working in underserved community clinics and federally qualified health centers to provide outreach, education and engagement on clinical trials. The Pipeline program will launch in the summer of 2022. Applications will open in Oct/Nov 2021.
Clinical research focus areas	Cancer (Hematology and Oncology), Cardiovascular Disease and Immunologic Disorders
Site diversity	Scholars may be practicing in urban centers / known clinical trial sites, and rural and/or trial naïve sites .
Annual convening	An annual event will bring key stakeholder groups together to inspire, educate, amplify and celebrate. Scholars will present their investigator-initiated clinical trial protocols in their second program year.

Candidate Eligibility Criteria

Candidate Profile	Eligible candidates will reflect the National Science Foundation (NSF) definition of underrepresented populations in the US Biomedical, Clinical, Behavioral and Social Sciences Research Enterprise: • African Americans or Blacks • Hispanics or Latinos • American Indians or Alaska Natives • Native Hawaiians • Other Pacific Islanders OR have a demonstrated commitment to increasing diverse patient participation in clinical trials
Citizenship or Immigration Status	Eligible candidates will be US Citizens or Lawful Permanent Residents (LPRs) as defined by the US Department of Homeland Security NOTE: J-1, O-1 & H-1B Visa holders are eligible; the visa must be valid during the full 2-yr period.
Professional Degree	Eligible candidates will hold the degree of MD, MD/PhD, DO or DO/PhD
Career Phase	Early Stage Investigator (ESI): As defined by NIH, a new investigator who has completed his or her terminal research degree or medical residency—whichever date is later—within the past 10 years and has not yet competed successfully for a substantial, competing NIH research grant. (Applicants with an RO1 or RO1 equivalent are ineligible.)

BMSF DCTCDP: Timeline



How to Apply to the BMSF DCTCDP

Application Process with Key Target Dates

The BMSF DCTCDP application will be a 2-step process, which includes:

1) Submission of a Letter of Intent (LOI), and
2) Upon review, selected candidates will be **invited to submit a full Application.**

Application Process Opens: Letter of Intent & Invited Full Application	Jan 4, 2021
Application Closes:	July 2, 2021
Selection Process:	July 2-Aug 31, 2021
Selection Announcement:	Sep 1, 2021
First Cohort Begins:	Oct 2021

Note: Dates are subject to change.

Letter of Intent - Step 1

- Degree and dates received
- List clinical specialty and sub-specialty
- Self-identify racial or ethnic minority group OR indicate Other and describe your demonstrated commitment to diversity in clinical trials
- Identify Citizenship/Immigration Status
- Position/Job title and start date
- Name and location of institution/organization
- Does your institution support your application?
- Do you have a potential mentor identified at your institution with whom you can participate on an ongoing clinical trial?
- List all current sources of funding
- List all significant publications within the last 2-3 years
- Submit current CV (within 6 months)
- Indicate your experience with the design of clinical trials studies or participation in clinical trial research
- Provide a brief description of the research you aspire to participate in during the 2-yr BMSF DCTCDP (limit 300 words)
- Provide a brief description of how you see this program advancing your career and your ability to contribute to increasing diversity in clinical trials (limit 300 words)

National Advisory Committee (NAC)

CHAIR
Robert Winn, MD
Director, Massey Cancer Center
Senior Associate Dean for Cancer Innovation
Professor, Division of Pulmonary Disease and Critical Care Medicine
Virginia Commonwealth University

MEMBERS
Leon Bernal-Mizrachi, MD
Associate Professor, Department of Hematology & Medical Oncology
Service Chief, Hematology and Medical Oncology
Associate Director, Hematology and Medical Oncology Fellowships Program
Emory University School of Medicine & Grady Health Systems

Nancy Daly, RN, MS, MPM
Executive Vice President & Chief Executive Officer
Conquer Cancer and the ASCO Foundation

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine
Professor of Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Yale Comprehensive Cancer Center
Yale School of Medicine

Gail Kerr, MD, FRCP
Professor of Medicine & Chief of Rheumatology at Howard University Hospital
Howard University

José López, MD
Chief Scientific Officer & Full Member
Blood Works Northwest Research Institute
Professor of Medicine, Division of Hematology
University of Washington School of Medicine

Ruben Mesa, MD, FACP
Presidential Chair, Mays Family Foundation Distinguished University
Director, Mays Cancer Center
Professor of Medicine
UT Health San Antonio MD Anderson

Lucio Miele, MD, PhD
Professor and Department Head, LSU School of Medicine, Department of Genetics
Director for Inter-Institutional Programs, LSU Stanley Scott Cancer Center & Louisiana Cancer Research Consortium
Cancer Crusaders Endowed Professor in Cancer Research
Louisiana State University Health Sciences Center

Edith Mitchell, MD, MACP, FCPP
Clinical Professor of Medicine and Medical Oncology
Director, Center to Eliminate Cancer Disparities
Associate Director, Diversity Affairs
Sidney Kimmel Cancer Center at Jefferson Health

Kathryn Owen
Vice President
Head of Global Development Operations
Bristol Myers Squibb

Eliseo J. Pérez-Stable, MD
Director, National Institute on Minority Health and Health Disparities
National Institutes of Health

Lori Pierce, MD
Professor, Department of Radiation Oncology
Vice Provost for Academic and Faculty Affairs
Michigan Medicine, University of Michigan

Amelie G. Ramirez, DrPH, MPH
Director & Professor, Institute for Health Promotion Research, Graduate School of Biomedical Sciences
UT Health San Antonio

Brian Rivers, PhD, MPH
Director, Cancer Health Equity Institute, National Center for Primary Care
Morehouse School of Medicine

Hannah Valantine, MD
Professor, Cardiovascular Medicine
Stanford University Medical Center
Prior: Chief Officer for Scientific Workforce Diversity, National Institutes of Health

Annabelle Volgman, MD, FACC, FAHA
McMullan-Eybel Chair of Excellence in Clinical Cardiology
Professor of Medicine, Rush College of Medicine
Medical Director, Rush Heart Center for Women
Rush University

Karen Winkfield, MD, PhD
Executive Director
Meharry-Vanderbilt Alliance
Vanderbilt University Medical Center

Winston Wong, MD, MS, FAAFP
Scholar-in-Residence, UCLA Kaiser Permanente Center for Health Equity
UCLA Fielding School of Public Health

QUESTIONS

Thank you for your interest in the BMS Foundation DCTCDP!

Letter of intent:
https://nmf.smapply.io/prog/bmsf-dctcdp/

Direct inquiries to: DCTCDPinfo@nmfonline.org

Program website: www.diversityinclinicaltrials.org